Postoperative complications in relation with induction therapy for lung cancer

被引:53
作者
Doddoli, C [1 ]
Thomas, P
Thirion, X
Serée, Y
Giudicelli, R
Fuentes, P
机构
[1] St Marguerite Univ Hosp, Dept Thorac Surg, Marseille, France
[2] St Marguerite Univ Hosp, Dept Biostat & Med Informat, Marseille, France
关键词
cancer; surgery; radiotherapy; chemotherapy; neoadjuvant; complications;
D O I
10.1016/S1010-7940(01)00764-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The purpose of this study was to evaluate the risk of lung cancer surgery following induction chemotherapy and/or radiotherapy. Methods: This retrospective study included 69 patients treated from January 1990 to January 1998 for a primary lung cancer in whom surgery had been performed after induction treatment. Surgery had not been considered initially for the following reasons: N2 disease (IIIA, n = 25); temporary functional impairment (two stages IB and two stages IIIA (N2), n = 4); and doubtful resectability (stage IIIB (T4), n = 40). The medical regimen resulted in combined radio-chemotherapy in 43 patients who received two to four cycles of chemotherapy (average 2.9 +/- 0.8 cycles) and 43 +/- 8 Gy (range 20-60 Gy), or chemotherapy alone in 26 patients (3 +/- 0.7 cycles). Results: Exploratory thoracotomy was performed in four patients (6%). The in-hospital mortality was 9% (n = 6) from respiratory origin in all cases. There were four re-operations (6%): three for bronchial fistula and one for bleeding. Thirty-five patients (51 %) required blood transfusion (4.5 +/- 3.8 cell packs). The incidence of early and delayed bronchial fistula after pneumonectomy was 15%. Thirteen patients had a postoperative pneumonia (19%). Conclusions: Surgery for lung cancer after induction chemotherapy and/or radiotherapy is associated with an increased risk. If the mortality seems 'acceptable', the morbidity rate, however, is high. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:385 / 390
页数:6
相关论文
共 26 条
[21]   RESULTS OF CANCER AND LEUKEMIA GROUP-B PROTOCOL-8935 - A MULTIINSTITUTIONAL PHASE-II TRIMODALITY TRIAL FOR STAGE-IIIA (N2) NON-SMALL-CELL LUNG-CANCER [J].
SUGARBAKER, DJ ;
HERNDON, J ;
KOHMAN, LJ ;
KRASNA, MJ ;
GREEN, MR .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1995, 109 (03) :473-485
[22]  
THOMAS P, 1992, REV MAL RESPIR, V9, P531
[23]  
TWOHIG KJ, 1990, CLIN CHEST MED, V11, P31
[24]   SURGICAL-TREATMENT FOR HIGHER STAGE NON-SMALL-CELL LUNG-CANCER [J].
VANRAEMDONCK, DE ;
SCHNEIDER, A ;
GINSBERG, RJ .
ANNALS OF THORACIC SURGERY, 1992, 54 (05) :999-1013
[25]   Present status of induction treatment in stage IIIA-N2 non-small cell lung cancer: A review [J].
Vansteenkiste, J ;
De Leyn, P ;
Deneffe, G ;
Menten, J ;
Lerut, T ;
Demedts, M .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 1998, 13 (01) :1-12
[26]  
WAGNER H, 1994, CHEST, V106, pS348